In vitro activity of tigecycline against MRSA, vancomycin-resistant enterococci, and extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates collected in the Czech Republic
Abstract number: P592
Zemlickova H., Urbaskova P.
Objectives: To describe the antimicrobial susceptibility to tigecycline in the Czech Republic among isolates of meticillin-resistant Staphylococcus aureus (MRSA), extended spectrum b-lactamases (ESBL) producing Escherichia coli (n = 90) and Klebsiella pneumoniae (n = 100) and vancomycin-resistant enterococci (VRE) (n = 111).
Methods: The isolates were collected in 36 microbiological laboratories partipating in the European Antimicrobial Resistance Surveillance System (EARSS) in the Czech Republic in 20002007. The isolates of MRSA (n = 105) and ESBL-producing K. pneumoniae (n = 100) were collected from blood. The isolates of ESBL-producing E. coli originated from blood (n = 19), urine (11), and wound infections (5). VRE isolates were collected from blood (25), sputum (9), wound (39), urine (34), and stool (5) specimens. A single isolate per patient was accepted. In vitro MICs were determined according to the CLSI (formerly NCCLS) guidelines. The criteria of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) were used to interpret MIC results.
Results: All VRE, MRSA, and ESBL-producing E. coli strains were susceptible to tigecycline using EUCAST breakpoints, i.e. 0. 25 mg/l, 0.5 mg/l and 1 mg/l, respectively. As many as 93% of ESBL-producing K. pneumoniae strains were inhibited by 1mg/l of tigecycline and five such strains were inhibited by 2 mg/l. Two K. pneumoniae strains were resistant to tigecycline with MICs of 4 mg/l.
Conclusion: In the Czech Republic, tigecycline has a good activity against MRSA, VRE, and ESBL-producing isolates of E. coli. Strains intermediately resistant (5%) and resistant (2%) to tigecycline were found among ESBL-producing K. pneumoniae isolates.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|